InfuSystem Holdings, Inc (INFU) Stock Analysis and Metrics

InfuSystem Holdings

NYSE: INFU

$9.11 ▲ +0.22 (+2.47%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap179.47 Mn

P/E22.61

P/S1.26

Div. Yield0.00

Total Debt (Qtr)19.65 Mn

Revenue Growth (1y) (Qtr)-2.97

Add ratio to table…

About

InfuSystem Holdings, Inc. is a leading national healthcare service provider facilitating outpatient care for Durable Medical Equipment manufacturers and healthcare providers. The company delivers products and services enabling clinic-to-home healthcare solutions, particularly for complex DME requiring ongoing treatment. Its operations are centered on two core platforms: Patient Services and Device Solutions, which together support healthcare providers in managing infusion therapies and related equipment needs across outpatient settings.

InfuSystem Holdings, Inc. generates revenue primarily through the rental, sale, and servicing of ambulatory and pole-mounted infusion pumps, along with associated disposable supply kits and biomedical services. Revenue is derived from billing third-party payers, healthcare facilities, and patients for the use of equipment and related consumables, including chemotherapy infusion supplies and wound care products. The company serves hospitals, oncology practices, ambulatory surgery centers, home care providers, and other alternate site healthcare providers across the United States and Canada.

The company operates through the following segments: Patient Services and Device Solutions.

• Patient Services: This segment focuses on delivering turnkey clinic-to-home healthcare solutions involving Durable Medical Equipment, including electronic ambulatory infusion pumps and associated disposable supply kits. The leading service within this segment is the Oncology Business, which supplies pumps and kits to private oncology clinics, infusion clinics, and hospital outpatient oncology clinics for cancer treatment. In 2025, the Oncology Business generated approximately 87% of the Patient Services segment’s net revenues, with 43% from colorectal cancer treatments and 44% from non-colorectal disease states. The segment also provides pain management services using continuous peripheral nerve block therapy, Negative Pressure Wound Therapy devices from manufacturers such as Smith and Nephew, Cork Medical LLC, and Genadyne Biotechnologies Inc., and Pneumatic Compression Devices. Additional activities include pursuing acquisitions of regional healthcare service providers, forming partnerships like SI Healthcare Technologies LLC with Sanara MedTech Inc., and offering information technology-based services such as EXPRESS, InfuConnect, DeviceHub, BlockPain Dashboard®, and Tracking Inhouse Management to streamline billing and clinical operations.

• Device Solutions: This segment provides rental, sale, and leasing services for new and pre-owned pole-mounted and ambulatory infusion pumps, along with treatment-related consumables. It also offers biomedical recertification, maintenance, and repair services for infusion pumps and other DME equipment used by oncology practices, hospitals, home care providers, skilled nursing facilities, and pain centers. The segment includes servicing equipment acquired through acquisitions such as FilAMed and OB Healthcare Corporation, which expanded its biomedical service capabilities. As of December 31, 2025, the rental fleet had a historical cost of $109.1 million and included approximately 96 makes and models of equipment, while the fleet held for sale or rental was valued at $4.6 million. The company operates biomedical service Centers of Excellence, including a primary facility in Lenexa, Kansas, and deploys field-based and traveling technicians to provide on-site maintenance and repair services nationwide.

InfuSystem Holdings, Inc. holds a strong position in the Durable Medical Equipment industry, particularly in outpatient oncology infusion services, where it leverages long-standing relationships with healthcare providers and a broad network of third-party payer contracts. The company competes with national, regional, and hospital-owned DME providers, physician-owned infusion services, and home care infusion companies. Competitive advantages include its extensive third-party payer network—nearly 840 contracts as of December 31, 2025—economies of scale in pump procurement and management, a large and responsive fleet of infusion pumps, seven geographic locations enabling rapid delivery, and a skilled biomedical service team. These barriers to entry are reinforced by the company’s reputation for high service levels and its focus on revenue cycle management and clinical support.

InfuSystem Holdings, Inc. serves hospitals, oncology practices, ambulatory surgery centers, home care providers, skilled nursing facilities, pain centers, and other alternate site healthcare providers. The company maintains business relationships with clinical oncologists in approximately 2,100 outpatient oncology clinics as of December 31, 2025. No single payer or customer accounted for more than 10% of net revenue in 2025 or 2024, indicating a diversified customer base across various healthcare settings and payer types, including Medicare, Medicaid, commercial insurers, and self-insured plans.

Investment Thesis

▲ Bull case

InfuSystem is strategically positioned to capitalize on accelerating demand in high-growth therapy areas beyond its traditional oncology base, particularly Wound Care, which delivered over 160% revenue growth in Q4 2025 and 116% year-over-year growth in Q1 2026. This expansion is being fueled by new supplier relationships for Pneumatic Compression Devices and Adjustable Compression Wraps, which together represented over 60% of Wound Care growth in the latest quarter. The company is leveraging its established logistics and service infrastructure to rapidly scale these offerings without proportional increases in capital intensity, as evidenced by declining capital expenditures despite revenue growth. The shift toward lower-capital, higher-margin therapy areas like Wound Care provides a structural tailwind that could allow InfuSystem to sustain mid-to-high single-digit revenue expansion while improving overall portfolio profitability, a dynamic the market may be underappreciating as it focuses narrowly on the headline GAAP revenue decline from contract restructuring. The successful go-live of the new ERP system on March 1, 2026, represents a transformational operational upgrade that is expected to unlock significant efficiency gains across the business, including improved productivity, better cost and margin visibility, stronger pricing insights, and more efficient utilization of the medical device fleet. Management emphasized that while early-stage adjustments are expected, the hardest part of the implementation is behind them, and the system now provides a scalable platform for future growth. These benefits are anticipated to reduce ongoing G&A expenses as a percentage of revenue and improve working capital management, with the company already identifying enhancements offering fast payback and high returns. The market may be underestimating the cumulative impact of this investment, which, combined with disciplined capital allocation and ongoing share repurchases, could drive meaningful margin expansion and free cash flow conversion in 2026 and beyond, supporting long-term value creation. InfuSystem’s balance sheet strength and disciplined capital allocation provide a durable foundation for shareholder returns, with net debt declining 30% year-over-year to $16.4 million as of December 31, 2025, and operating cash flow increasing 19.3% to $24.4 million for the full year 2025. The company has returned capital through its share repurchase program, retiring 1.3 million shares for the full year 2025 and an additional $0.8 million in Q1 2026, while maintaining ample liquidity of $57.1 million as of March 31, 2026. The recent authorization of a new $20 million share repurchase program running through June 2028 underscores management’s confidence in sustained cash generation and commitment to enhancing shareholder value. This financial flexibility, coupled with a focus on profitable growth over pure revenue expansion, allows InfuSystem to navigate near-term headwinds while positioning for accelerated performance as the benefits of strategic initiatives mature, a resilience the market may not be fully pricing in.

InfuSystem is strategically positioned to capitalize on accelerating demand in high-growth therapy areas beyond its traditional oncology base, particularly Wound Care, which delivered over 160% revenue growth in Q4 2025 and 116% year-over-year growth in Q1 2026. This expansion is being fueled by new supplier relationships for Pneumatic Compression Devices and Adjustable Compression Wraps, which together represented over 60% of Wound Care growth in the latest quarter. The company is leveraging its established logistics and service infrastructure to rapidly scale these offerings without proportional increases in capital intensity, as evidenced by declining capital expenditures despite revenue growth. The shift toward lower-capital, higher-margin therapy areas like Wound Care provides a structural tailwind that could allow InfuSystem to sustain mid-to-high single-digit revenue expansion while improving overall portfolio profitability, a dynamic the market may be underappreciating as it focuses narrowly on the headline GAAP revenue decline from contract restructuring. The successful go-live of the new ERP system on March 1, 2026, represents a transformational operational upgrade that is expected to unlock significant efficiency gains across the business, including improved productivity, better cost and margin visibility, stronger pricing insights, and more efficient utilization of the medical device fleet. Management emphasized that while early-stage adjustments are expected, the hardest part of the implementation is behind them, and the system now provides a scalable platform for future growth. These benefits are anticipated to reduce ongoing G&A expenses as a percentage of revenue and improve working capital management, with the company already identifying enhancements offering fast payback and high returns. The market may be underestimating the cumulative impact of this investment, which, combined with disciplined capital allocation and ongoing share repurchases, could drive meaningful margin expansion and free cash flow conversion in 2026 and beyond, supporting long-term value creation. InfuSystem’s balance sheet strength and disciplined capital allocation provide a durable foundation for shareholder returns, with net debt declining 30% year-over-year to $16.4 million as of December 31, 2025, and operating cash flow increasing 19.3% to $24.4 million for the full year 2025. The company has returned capital through its share repurchase program, retiring 1.3 million shares for the full year 2025 and an additional $0.8 million in Q1 2026, while maintaining ample liquidity of $57.1 million as of March 31, 2026. The recent authorization of a new $20 million share repurchase program running through June 2028 underscores management’s confidence in sustained cash generation and commitment to enhancing shareholder value. This financial flexibility, coupled with a focus on profitable growth over pure revenue expansion, allows InfuSystem to navigate near-term headwinds while positioning for accelerated performance as the benefits of strategic initiatives mature, a resilience the market may not be fully pricing in.

▼ Bear case

InfuSystem’s reliance on restructuring its largest biomedical services contract with GE Healthcare introduces significant near-term revenue volatility and execution risk, as the company began 2026 with a reduced revenue volume of $1.6 million (4.6%) in Q1 and expects an annualized reduction of $7.1 million (5.5%) for the full year. While management frames this as a profitability-enhancing move, the actual margin improvement remains uncertain, particularly given that Device Solutions gross profit declined 10% in Q1 2026 despite a 3.4% gross margin increase, driven by an unfavorable product mix shift away from higher-margin rental and used equipment sales. The company’s ability to offset lost revenue with expense reductions depends on precise cost restructuring, and any shortfall in expected savings—especially if biomedical personnel reductions or travel expense cuts are not fully realized—could pressure Adjusted EBITDA, which was only flat year-over-year in Q1 2026 despite the revenue decline. The market may be overlooking the risk that this strategic shift fails to deliver the anticipated earnings inflection, leaving the company with lower top-line growth and unproven margin expansion. The Wound Care segment, while exhibiting high growth rates, remains a small and potentially low-margin contributor to overall profitability, representing just 6% of total revenue in Q1 2026 despite 116% year-over-year growth. The increase in Wound Care revenue has been accompanied by an unfavorable product mix in the Patient Services segment, which pulled down gross margin by favoring lower-margin therapy categories, and management acknowledged that pump disposal and maintenance expenses—while down in Q1—are subject to variability based on equipment failure rates and reserve adjustments. Furthermore, the growth in Wound Care is heavily dependent on new supplier relationships for compression devices, which introduces supply chain and integration risks; if these partnerships fail to scale or if reimbursement pressures emerge in home-based wound therapy, the segment’s rapid expansion could stall, leaving InfuSystem overexposed to a niche area that may not meaningfully contribute to consolidated profitability in the near term. Ongoing investments in the ERP system upgrade, while framed as transformational, continue to pressure near-term profitability, with G&A expenses related to information technology and business applications increasing by $0.4 million in Q1 2026 due to heightened go-live phase activities. Although management expects these costs to taper post-implementation, the company has a history of underestimating the duration and expense of such transformations, as the ERP project launched in Q2 2024 and only went live in Q1 2026—nearly two years after initiation. Any delays in stabilization, unexpected post-go-live enhancement costs, or failure to realize the promised efficiencies in pricing, utilization, or working capital could prolong the drag on margins. Additionally, rising healthcare benefit costs and wage inflation are eroding gross margin improvements in Device Solutions, with combined wage and healthcare cost increases reducing the segment’s gross margin by 2.5% in Q1 2026, suggesting that inflationary pressures may be outpacing operational savings, a risk the market may be underestimating as it focuses on long-term benefits of the ERP rollout.

InfuSystem’s reliance on restructuring its largest biomedical services contract with GE Healthcare introduces significant near-term revenue volatility and execution risk, as the company began 2026 with a reduced revenue volume of $1.6 million (4.6%) in Q1 and expects an annualized reduction of $7.1 million (5.5%) for the full year. While management frames this as a profitability-enhancing move, the actual margin improvement remains uncertain, particularly given that Device Solutions gross profit declined 10% in Q1 2026 despite a 3.4% gross margin increase, driven by an unfavorable product mix shift away from higher-margin rental and used equipment sales. The company’s ability to offset lost revenue with expense reductions depends on precise cost restructuring, and any shortfall in expected savings—especially if biomedical personnel reductions or travel expense cuts are not fully realized—could pressure Adjusted EBITDA, which was only flat year-over-year in Q1 2026 despite the revenue decline. The market may be overlooking the risk that this strategic shift fails to deliver the anticipated earnings inflection, leaving the company with lower top-line growth and unproven margin expansion. The Wound Care segment, while exhibiting high growth rates, remains a small and potentially low-margin contributor to overall profitability, representing just 6% of total revenue in Q1 2026 despite 116% year-over-year growth. The increase in Wound Care revenue has been accompanied by an unfavorable product mix in the Patient Services segment, which pulled down gross margin by favoring lower-margin therapy categories, and management acknowledged that pump disposal and maintenance expenses—while down in Q1—are subject to variability based on equipment failure rates and reserve adjustments. Furthermore, the growth in Wound Care is heavily dependent on new supplier relationships for compression devices, which introduces supply chain and integration risks; if these partnerships fail to scale or if reimbursement pressures emerge in home-based wound therapy, the segment’s rapid expansion could stall, leaving InfuSystem overexposed to a niche area that may not meaningfully contribute to consolidated profitability in the near term. Ongoing investments in the ERP system upgrade, while framed as transformational, continue to pressure near-term profitability, with G&A expenses related to information technology and business applications increasing by $0.4 million in Q1 2026 due to heightened go-live phase activities. Although management expects these costs to taper post-implementation, the company has a history of underestimating the duration and expense of such transformations, as the ERP project launched in Q2 2024 and only went live in Q1 2026—nearly two years after initiation. Any delays in stabilization, unexpected post-go-live enhancement costs, or failure to realize the promised efficiencies in pricing, utilization, or working capital could prolong the drag on margins. Additionally, rising healthcare benefit costs and wage inflation are eroding gross margin improvements in Device Solutions, with combined wage and healthcare cost increases reducing the segment’s gross margin by 2.5% in Q1 2026, suggesting that inflationary pressures may be outpacing operational savings, a risk the market may be underestimating as it focuses on long-term benefits of the ERP rollout.

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password